HALO — Halozyme Therapeutics Inc. stock price and chart

Share this page

HALO

$109.86+2.73%

as of close, Oct 2, 2026

☾ AH $109.86 +2.73%

Halozyme Therapeutics Inc.Stock · Health CareNasdaq Composite 0.02%Russell 3000 0.01%Russell 1000 0.01%US Stock Market 0.01%

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

10.020.030.040.050.060.070.080.090.0100.0110.0020.0M40.0M$109.86

2026-10-02

Price$109.86

MA20$84.83

MA50$75.50

Vol15.5M

What would $1,000 invested in HALO be worth today? →

HALO returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $109.86
Change YTD: +63.24%
Next earnings: Nov 2, 2026
Market cap: 12.5B2016-12 1.3B2026-10 12.5B+874.5% over the window
Enterprise value: 14.5B
Shares outstanding: 113.5M2016-06 129.4M2026-06 113.5M-12.3% over the window
52W low: $61.23
52W high: $116.85
From 52W high: -5.98%
From 52W low: +79.42%
52W range: 87%
Beta: 0.85

Volume

Rel volume: 1.17×
30D volume: 2.2M
30D $ vol: 244.6M

Insider trading

Insider net 1W0 insider-days of buying (no priced lot) and 1 of selling ($568K) in the last 7 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$568K
Insider net 1M0 insider-days of buying (no priced lot) and 5 of selling ($9.1M) in the last 30 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$9.1M
Insider net 3M0 insider-days of buying (no priced lot) and 10 of selling ($15.6M) in the last 91 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$15.6M
Insider net 1Y0 insider-days of buying (no priced lot) and 32 of selling ($36.0M) in the last 365 days, by transaction date, open-market transactions only — awards, exercises, tax withholding and employee-plan purchases are not counted. A Form 4 is filed within two business days of the trade, so the newest days may not be in yet.: −$36.0M

Form 4 transactions by trade date, as filed; latest on file 2026-10-01.

Fundamentals

Sales (ttm): 1.7B2016-06 146.7M2026-06 1.7B+1034.2% over the window
Sales/share: $14.662016-06 $1.132026-06 $14.66+1193.2% over the window
EPS (ttm): $3.392016-06 -$0.262026-06 $3.39-1402.1% over the window
FCF (ttm): 806.2M2016-06 -62.3M2026-06 806.2M-1394.4% over the window
FCF/share: $7.102016-06 -$0.482026-06 $7.10-1575.9% over the window
Book value/share: $1.262016-06 $0.082026-06 $1.26+1549.9% over the window
Net margin: 24.86%2016-06 -70.2%2026-06 24.9%-135.4% over the window
ROE: 288.13%2016-06 -1038.5%2026-06 288.1%-127.7% over the window
ROA: 16.05%2016-06 -34.8%2026-06 16.0%-146.1% over the window
Debt / equity: 13.50×2016-06 20.652026-06 13.50-34.6% over the window
Current ratio: 2.712016-06 7.312026-06 2.71-63.0% over the window

Growth (CAGR, ttm) · 10Y

Sales: +41.19%2025-06-30 → 2026-06-301.2B → 1.7B (+41.2% total)+29.07%2023-06-30 → 2026-06-30773.7M → 1.7B (+115.0% total)+32.18%2021-06-30 → 2026-06-30412.5M → 1.7B (+303.3% total)+27.49%2016-06-30 → 2026-06-30146.7M → 1.7B (+1034.2% total)
Net income: -25.80%2025-06-30 → 2026-06-30557.3M → 413.6M (-25.8% total)+20.95%2023-06-30 → 2026-06-30233.7M → 413.6M (+77.0% total)+12.58%2021-06-30 → 2026-06-30228.7M → 413.6M (+80.8% total)n/a
FCF: +49.15%2025-06-30 → 2026-06-30540.7M → 806.2M (+49.1% total)+40.15%2023-06-30 → 2026-06-30292.8M → 806.2M (+175.4% total)+40.08%2021-06-30 → 2026-06-30149.5M → 806.2M (+439.2% total)n/a
Shares: -2.97%2025-06-30 → 2026-06-30117M → 113.5M (-3.0% total)-4.89%2023-06-30 → 2026-06-30131.9M → 113.5M (-14.0% total)-4.43%2021-06-30 → 2026-06-30142.3M → 113.5M (-20.3% total)-1.30%2016-06-30 → 2026-06-30129.4M → 113.5M (-12.3% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: -22.55%2025-06-30 → 2026-06-30$4.37 → $3.39 (-22.5% total)+25.83%2023-06-30 → 2026-06-30$1.70 → $3.39 (+99.3% total)+16.76%2021-06-30 → 2026-06-30$1.56 → $3.39 (+117.0% total)n/a
Sales/share: +45.50%2025-06-30 → 2026-06-30$10.08 → $14.66 (+45.5% total)+35.70%2023-06-30 → 2026-06-30$5.86 → $14.66 (+150.0% total)+38.30%2021-06-30 → 2026-06-30$2.90 → $14.66 (+405.8% total)+29.18%2016-06-30 → 2026-06-30$1.13 → $14.66 (+1193.2% total)
FCF/share: +53.71%2025-06-30 → 2026-06-30$4.62 → $7.10 (+53.7% total)+47.36%2023-06-30 → 2026-06-30$2.22 → $7.10 (+220.1% total)+46.57%2021-06-30 → 2026-06-30$1.05 → $7.10 (+576.2% total)n/a
Book value/share: -55.57%2025-06-30 → 2026-06-30$2.84 → $1.26 (-55.5% total)+3.37%2023-06-30 → 2026-06-30$1.14 → $1.26 (+10.5% total)+8.50%2021-06-30 → 2026-06-30$0.84 → $1.26 (+50.3% total)+32.36%2016-06-30 → 2026-06-30$0.08 → $1.26 (+1549.9% total)
Price: +53.29%2025-10-02 → 2026-10-02$71.69 → $109.86 (+53.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+42.84%2023-10-02 → 2026-10-02$37.69 → $109.86 (+191.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+21.93%2021-10-01 → 2026-10-02$40.75 → $109.86 (+169.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+24.69%2016-09-30 → 2026-10-02$12.08 → $109.86 (+809.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +53.29%2025-10-02 → 2026-10-02$71.69 → $109.86 (+53.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+42.84%2023-10-02 → 2026-10-02$37.69 → $109.86 (+191.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+21.93%2021-10-01 → 2026-10-02$40.75 → $109.86 (+169.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+24.69%2016-09-30 → 2026-10-02$12.08 → $109.86 (+809.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 32.5×2016-12 -12.422026-10 30.14-342.7% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 20.9×2016-12 -23.192026-10 20.88-190.0% over the window
Fwd P/E: 10.9×
P/S (ttm)Market cap ÷ TTM revenue.: 7.5×2016-12 8.722026-10 7.49-14.1% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 86.9×2016-12 -106.682026-10 86.86-181.4% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 15.5×2016-12 -23.632026-10 15.46-165.4% over the window
EV/EBITDA (fy): 23.7×
EV/Sales (ttm): 8.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 6.47%2016-09 -4.2%2026-06 9.1%-314.5% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 113.5M ÷ 117.0M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 2.97%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (2.97%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($6.1B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 2.97%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($371.6M) ÷ today's market cap ($12.5B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 2.98%2016-09 0.0%2026-06 4.2%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $371.6M + TTM dividends $0) ÷ today's market cap ($12.5B). Same caveat as the cash buyback yield.: 2.98%2016-09 0.0%2026-06 4.2%

Vs own 10Y history

P/E: 70th
P/OI: 60th
P/S: 31st
P/B: 94th
P/FCF: 34th

Bar = where today’s multiple sits in HALO’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-02

+2.73%

-3.55%

+0.18%

+38.28%

YTD

+63.24%

+53.24%

+169.60%

Recent filings

Oct 1Insider sale · Posard Matthew L. (Director) sold 5,230 shares for $568K at $107.17–$110.04 under a 10b5-1 plan
Sep 308-K · Directors or officers; compensation
Sep 228-K · Material definitive agreement; New financial obligation; Unregistered sale of equity
Sep 188-K · Other events
Sep 16Insider sale · Posard Matthew L. (Director) sold 18,996 shares for $2.0M at $106.13–$108.99 under a 10b5-1 plan

All filings and insider trades →

Financial statements

Open full HALO financials →

Loading financial statements…

Ticker	Name	1M	1D
NVS	Novartis AG	-13.21%	-0.04%
NVO	Novo Nordisk A/S	-20.21%	-0.21%
SNY	Sanofi ADS	-10.23%	-1.84%
GSK	GSK plc American Depositary Shares (Each representing two Ordinary Shares)	-6.76%	-0.32%
NTRA	Natera Inc.	+26.20%	+0.46%
ARGX	argenx SE American Depositary Shares	-12.90%	-1.79%
TAK	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	-3.09%	+0.00%
TEVA	Teva Pharmaceutical Industries Limited American Depositary Shares	+5.44%	+0.56%

HALO — Halozyme Therapeutics Inc. price, chart and key statistics